Tinea pedis is an infection of the skin that causes itching, scaling, flaking, and blistering of the interdigital spaces of the foot. The prevalence of tinea pedis increases with age, and estimates suggest that 70% of the population will be affected by tinea pedis at some point in their life. Tinea pedis can currently be treated with oral antifungal medicines (taken by mouth), topical treatments applied directly to the skin, or a combination of both. Topical antifungal agents, many available over the counter, are generally used more frequently and are applied for 1-6 weeks.
Blueberry is developing a new, topical antifungal spray formulation (BB2603-tp) for the topical treatment of tinea pedis using our nanodelivery platform technology. By enhancing drug penetration into the upper layers of the skin, our aim is to be able to use significantly lower doses of an existing antifungal agent, but to match the efficacy and match or improve safety.
Information on Blueberry clinical trials in tinea pedis can be found on our clinical trials page.